CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase ...

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...